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Introduction:
What is the topic?
Malignant
Hyperthermia

•
•
•
•
•
•

•
•
•
•
•
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Why choose
Malignant
Hyperthermia?
•

•

•

•

Anesthesia providers and
perioperative nurses play a
pivotal role in the
identification and successful
management of the condition
For a patient to survive a
malignant hyperthermia crisis,
prompt recognition and
treatment is vital (Mullins,
2018)
With proper education and
understanding of the
pathophysiology of the
disorder, negative patient
outcomes can be prevented
The understanding of MH is
essential as an anesthesia care
provider

Pathophysiological Processes

Presentation of Case/Process

•
•

•
•
•
•
•
•

A 20-year-old male patient presented following a motor vehicle crash with
altered mental status and a laceration to the parietal region of his head.
The prehospital care providers reported that the patient was the driver of a
vehicle that struck a concrete guardrail at a high speed.
Initial assessment revealed a GCS of 10 . The decision was made to intubate the
patient based on continued deterioration of his mental status
Vitals signs during intubation were stable at HR of 82 blood pressure 152/70,
SpO2 100%, and his temperature was not recorded prior to induction
Patient was preoxygenated with a non-rebreather mask and high-flow nasal
cannula and given 1.5 mg/kg of both ketamine and succinylcholine
After administration of the succinylcholine, the patient experienced prolonged
muscle fasciculations of his pectoral and abdominal muscles, and then
desaturated to 60% despite ongoing oxygenation with a nonrebreather mask
and nasal cannula
The patient’s glottic opening was easily visualized with a video laryngoscope,
and his vocal cords continued to abduct/adduct.
The emergency medicine resident was able to pass the tube successfully on the
first attempt.
The patient was then placed on continuous waveform capnography, and the
end-tidal CO2 (EtCO2) was 71 mmHg.
The patient also became tachycardic within 2 min of induction, with a heart rate
noted in the 150–160 range.
The treatment team initially felt the patient was inadequately sedated and
administered midazolam and fentanyl
Despite providing adequate ventilation and sedation, the patient remained
hypercapnic and tachycardic, with his EtCO2 ranging from 50 to 70 mmHg and
heart rate 140–160
The team suspected MH at this stage and activated the MH protocol. The
protocol, prompts a pharmacist to respond to the patient location with
dantrolene (Ryanodex) and cooling agents in a designated cart.
The patient’s CAT scan showed spinous process fractures and rib fractures;
there were no other injuries and no intracranial abnormality noted.
Bedside point-of-care chemistry revealed a potassium of 3.7,creatinine of 1.9,
venous pH of 7.19, PCO2 of 65 and bicarbonate of 25
The patient was administered 2.5 mg/kg of dantrolene. His temperature at this
time was 37.1◦C (98.8◦F)
Patient was admitted to the trauma intensive care unit and progressed to
extubation within 36 hr. postinjury
The patient continued to receive additional doses of dantrolene (Ryanodex) 250
mg every 6 hr. for 24 hr.
He was discharged on Day 7postinjury. Patient was neurologically intact and
scheduled to follow up for his orthopedic injuries
(Luckey-Smith & High, 2018)

Normal
Physiology
•

•

•

•

In a normal muscle contraction, an
action potential causes membrane
depolarization which releases
calcium from the sarcoplasmic
reticulum (SR).
The calcium moves into the
sarcoplasm via the ryanodine
receptors. The receptor is a
voltage-gated ion channels.
The calcium interacts with the
troponin-tropomyosin complex. It
creates the cross-bridge between
actin and myosin and a muscle
contraction occurs.
At the end of a muscle contraction,
calcium migrates back into the
sarcoplasmic reticulum , and
another stimulus is needed to
release calcium for a muscle
contraction ( Schneiderbanger et
al., 2014).

Underlying
Pathophysiology
•

•

•

•

•

MH is a rare yet life threatening
autosomal dominant disorder
(affected individual has one copy of a
mutant gene and one normal gene on
a pair of autosomal chromosomes)
(Nagelhout & Elishia, 2018, p. 773).
MH occurs because of a a mutation on
the ryanodine receptor, which is the
major calcium release channel of the
sarcoplasm reticulum (Nagelhout &
Elishia, 2018, p. 774).
The anesthetic agents trigger these
mutations, and in turn, cause an
atypical increase in release of calcium
from the sarcoplasmic reticulum of
skeletal muscle cells (Mullins, 2018)
This results in sustained muscle
contraction and abnormal muscle
metabolism.
The response leads to hypermetabolic
activity of increased oxygen
consumption, carbon dioxide
production, heat production, and
lactic acidic build up. Results can then
lead to systemic acidosis,
hyperkalemia, and hyperthermia
(Smith et. al, 2018).

Signs and Symptoms Implications
for nursing
MH may present anytime
during general anesthesia and
care cont.
the early postoperative phase

•

( Mullins, 2018)
Early and specific sign of MH is
an unexplained rise in end-tidal
CO2 levels with increased
ventilation. If succinylcholine is
used ,the rise in CO2 may be
more rapid (Smith, et al, 2018)
Other symptoms include,
tachycardia and dysrhythmia,
abrupt rise in core body
temperature, generalized
skeletal muscle rigidity and
rhabdomyolysis ( Smith et. al,
2018)
Progression of the crisis leads to
respiratory and metabolic
acidosis, increased serum
potassium, elevated creatine
kinase levels, and
myoglobinuria may occur. The
patient may also suﬀer from
acute renal failure and/or
disseminated intravascular
coagulation ( Smith et. al, 2018)

•

•

•

Implications for
nursing care
•

•

•

•
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The severity of a MH crisis
depends on how quickly the
disease process is suspected
and how rapidly an
appropriate treatment is
initiated ( Schneiderbanger et
al., 2014).
Nurses should coordinate staff
efforts toward three priorities:
dantrolene preparation,
cooling the patient, and
preparing for transport.
Priority of treatment begins
by hyperventilating the patient
with 100% oxygen and
administering a dose of
dantrolene sodium.
Dantrolene is a skeletal muscle
relaxant that depresses muscle
contraction by decreasing
intracellular calcium
concentration (National
Institute s of Health, 2018).
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•

Once stabilized, patient should be
prepared to go to the ICU ( Borth,
2019) à
§
decreased heart rate
§
decreased end-tidal
carbon dioxide
(EtCO2)
§
resolution of
hyperkalemia

•

Regular MH drills should be
performed to demonstrate that staff
can mobilize MH supplies (Borth,
2019)
It is required that anesthesia staff
along with the registered nurses
working in the PACU must know
the response plan for an MH event
(Borth, 2019)

•

•

Conclusion
•

•

•

•

•

•

The prevalence of MH is
estimated at 1:100,000
administered anesthetics, but
this is likely underreported. (
Borth, 2019)
Half of the patients diagnosed
with MH have received a prior
anesthetic without manifesting
MH. ( Borth, 2019)
Without treatment, the
mortality rate for an acute MH
episode is as high as 80% (
Borth, 2019)
Complications increase 3X per
every 2°C increase in
temperature and 1.6 X per 30minute delay in dantrolene
administration ( Borth, 2019)
All staff members involved in
the care of patients receiving
MH-triggering agents should
receive annual education on MH
treatment ( Borth, 2019)
Although MH is a rare medical
emergency, it is vital that
clinicians and patients are
prepared and educated for the
surgical procedure and the risk
for complications with a
detailed plan in place
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